The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care
Open accessAbstract
Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment–related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM. (JNCCN 2008;6[Suppl 1]:S1–S21)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCollum, A. D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.15.1160 · Cited by 146
Cited by
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., McGuire, D. B., Migliorati, C., Nicolatou‐Galitis, O., Peterson, D. E., et al. (2014) · Cancer · doi:10.1002/cncr.28592 · Cited by 1,110
Self-citationOral complications of cancer and cancer therapy: From cancer treatment to survivorship
Epstein, J. B., Thariat, J., Bensadoun, R., Barasch, A., Murphy, B. A., Kolnick, L., Popplewell, L., & Maghami, E. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21157 · Cited by 518
Mucositis: pathobiology and management
Villa, A., & Sonis, S. T. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000180 · Cited by 280
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., et al. (2015) · Drugs · doi:10.1007/s40265-015-0434-6 · Cited by 152
Metadata
- Authors
- Bensinger, W., Schubert, M., Ang, K.-K., Brizel, D., Brown, E., Eilers, J. G., Elting, L., Mittal, B. B., Schattner, M. A., Spielberger, R., Treister, N. S., & Trotti, A. M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2008-06
- Volume
- 6
- Issue
- S1
- Pages
- S-1-S-21
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2415725664
- Cited by
- 242
- References
- 1
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.